Cinnamaldehyde promotes mitochondrial function and reduces Aβ toxicity in neural cells

doi:10.5246/jcps.2016.08.068

Abstract

Abstract:

Cinnamon and its major active component, cinnamaldehyde, have been shown to be neuroprotective in models of Alzheimer’s disease (AD). To further investigate the mechanism of cinnamaldehyde, we investigated the effects of cinnamaldehyde focusing on mitochondrial function in SH-SY5Y neural cells. The results demonstrated that cinnamaldehyde could enhance neural cell viability with or without increased Aβ levels. Cinnamaldehyde facilitated the maintenance of normal mitochondrial morphology, preserved the mitochondrial membrane potential (ΔΨ_m), and reduced production of reactive oxygen species (ROS). Cinnamaldehyde also decreased the expression of dynamin-related protein 1 (Drp1), a protein critically involved in mitochondrial dynamics. In addition, cinnamaldehyde inhibited Aβ oligomerization, but it had no effects on Tau phosphorylation. In overall, cinnamaldehyde promoted mitochondrial function and inhibited Aβ toxicity, and these two properties may both contribute to the neuroprotective effect. These results suggest that cinnamaldehyde could be a potential nutriceutical in the prevention and even therapeutic treatment of AD as well as other aging-related metabolic syndromes.

Key words: Alzheimer’s disease, A&beta, oligomers, Mitochondria, Cinnamaldehyde

CLC Number:

R962

Supporting:

Lidan Bai, Xue Li, Qing Chang, Rui Wu, Jing Zhang, Xiaoda Yang. Cinnamaldehyde promotes mitochondrial function and reduces Aβ toxicity in neural cells[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 605-613.

References

[1] Ubhi, K.; Masliah, E. J. Alzheimer’s Dis. JAD. 2013, 33, S185-194.
[2] Folch, J.; Petrov, D.; Ettcheto, M.; Abad, S.; Sánchez-López, E.; García, M.L.; Olloquequi, J.; Beas-Zarate, C.; Auladell, C.; Camins, A. Neural. Plasticity. 2016, 2016, 1-15.
[3] Selkoe, D.J. Trends Neurosciences. 1993, 16, 403-409.
[4] Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Proc. Natl. Acad. Sci. USA. 1986, 83, 4913-4917.
[5] Grammas, P. J. Neuroinflammation. 2011, 8, 26.
[6] Zhu, X.; Raina, A.K.; Perry, G.; Smith, M.A. Lancet Neurology. 2004, 3, 219-226.
[7] Aleksandra, M.; Cezary, E. Prog. Neuropsycho-pharmacol. Biol. Psychiatry. 2011, 35, 320-330.
[8] Amtul, Z. Ageing Res. Rev. 2016, 25, 70-84.
[9] Yu, J.T.; Zhang, C. Neurotox. Res. 2016, 29, 197-200.
[10] Wu, T.Y.; Chen, C.P.; Jinn, T.R. Taiwanese J. Obstetrics Gynecology. 2011, 50, 131-135.
[11] Rao, P.V.; Gan, S.H. Evid. Based Complement. Alternat. Med. 2014, 2014, 642942.
[12] Mancini-Filho, J.; Van-Koiij, A.; Mancini, D.A.; Cozzolino, F.F.; Torres, R.P. Boll. Chim. Farm. 1998, 137, 443-447.
[13] Louis Kuoping, C.; Kuo-Feng, H.; Hsien-Yeh, H.; Sen, S.C.; Ju, Y.L.; Shang-Tzen, C. J. Agric. Food Chem. 2005, 53, 7274-7278.
[14] Tung, Y.T.; Chua, M.T.; Wang, S.Y.; Chang, S.T. Bioresource Tech. 2008, 99, 3908-3913.
[15] Tung, Y.T.; Yen PLLin, C.Y.; Chang, S.T. Pharma. Biology. 2010, 48, 1130-1136.
[16] Liesel, B.; Floris, I.; Fritz, R.; Eguaras, M.J. Bull. Insectology. 2008, 61, 1-4.
[17] Prabuseenivasan, S.; Jayakumar, M.; Ignacimuthu, S. BMC Complement. Altern. Med. 2006, 6, 165-165.
[18] Becerril, R.; Gómez-Lus, R.; Goñi, P.; López, P.; Nerín, C. Anal. Bioanal. Chem. 2007, 388, 1003-1011.
[19] Jianming, L.; Keqiang, Z.; Sangkil, N.; Anderson, R.A.; Richard, J.; Wei, W. Carcinogenesis. 2009, 31, 481-488.
[20] Blevins, S.M.; Leyva, M.J.; Brown, J.; Wright, J.; Scofield, R.H.; Aston, C.E. Diabetes Care. 2007, 30, 2236-2237.
[21] Alam, K.; Mahpara, S.; Mohammad Muzaffar, A.K.; Khan Nawaz, K.; Anderson, R.A. Diabetes Care. 2004, 26, 3215-3218.
[22] Mang, B.; Wolters, M.; Schmitt, B.; Kelb, K.; Lichtinghagen, R.; Stichtenoth, D.O.; Hahn, A. Euro. J. Clinical. Investigation. 2006, 36, 340-344.
[23] Crawford, P. J. Am. Board Fam. Med. 2009, 22, 507-512.
[24] Safdar, M.; Khan, A.; Siddique, M. Pakistan J. Nutrition. 2004, 5, 268-272.
[25] Kim, S.H.; Sun, H.H.; Choung, S.Y. J. Ethnopharmacology. 2006, 104, 119-123.
[26] Rahman, S.; Begum, H.; Rahman, Z.; Ara, F. J. Enam Medical College. 2013, 3.
[27] Xiaofang, P.; Ka-Wing, C.; Jinyu, M.; Bo, C.; Chi-Tang, H.; Clive, L.; Feng, C.; Mingfu, W. J. Agric. Food Chem. 2008, 56, 1907-1911.
[28] Peterson, D.W. J. Alzheimers Disease. 2009, 17, 585-597.
[29] George, R.C.; Lew, J.; Graves, D.J. J. Alzheimers Disease. 2013, 36, 21-40.
[30] Ott, A.; Stolk, R.P.; Harskamp, F.; Pols, H.A.; Hofman, A.; Breteler, M.M. Neurology. 2000, 53, 1937-1942.
[31] Maher, P.A.; Schubert, D.R. Expert Rev. Neurotherapeutics. 2009, 9, 617-630.
[32] Swerdlow, R.H.; Khan, S.M. Medical Hypotheses. 2004, 63, 8-20.
[33] Zhang, J.; Liu, Q.; Chen, Q.; Liu, N.Q.; Li, F.L.; Lu, Z.B.; Qin, C.; Zhu, H.; Huang, Y.Y.; He, W.; Zhao, B.L. FASEB J. 2006, 20, 1212-1214.
[34] Barltrop, J.A.; Owen, T.C.; Cory, A.H.; Cory, J.G. Bioorg. Med. Chem. Lett. 1991, 1, 611-614.
[35] Atwood, C.S.; Moir, R.D.; Huang, X.; Scarpa, R.C.; Bacarra, N.M.; Romano, D.M.; Hartshorn, M.A.; Tanzi, R.E.; Bush, A.I. J. Biological Chem. 1998, 273, 12817-12826.
[36] Zheng, K.M.; Zhang, J.; Zhang, C.L.; Zhang, Y.W.; Chen, X.C. Acta Pharma. Sinica. 2015, 36, 544-552.
[37] Wu, Z.; Zhu, Y.; Cao, X.; Sun, S.; Zhao, B. Mol. Neurobiol. 2014, 50, 986-996.
[38] Reddy, P.H. J. Alzheimer’s Disease. 2014, 40, 245-256.
[39] Kumar, A.; Singh, A. Pharmacol. Rep. 2015, 67, 195-203.
[40] Bakota, L.; Brandt, R. Drugs. 2016, 76, 301-313.
[41] Mancini, S.; Minniti, S.; Gregori, M.; Sancini, G.; Cagnotto, A.; Couraud, P.O.; Ordonez-Gutierrez, L.; Wandosell, F.; Salmona, M.; Re, F. Nanomedicine: Nanotechnology. Biology. Medicine. 2016, 12, 43-52.
[42] Starkov, A.A. Ann. NY Acad. Sci. 2008, 1147, 37-52.
[43] Diano, S.; Horvath, T.L. Trends. Molecul. Med. 2012, 18, 52-58.
[44] Qin, B.; Panickar, K.S.; Anderson, R.A. J. Diabetes Sci. Tech. 2010, 4, 685-693.
[45] Dawson, T.; Frydman-Marom, A.; Levin, A.; Farfara, D.; Benromano, T.; Scherze-Attali, R.; Peled, S.; Vassar, R.; Segal, D.; Gazit, E.; Frenkel, D.; Ovadia, M. PloS One. 2011, 6, e16564.